Sites not expected to fade away even as DCTs continue to grow past COVID-19.
William Chaplin
Advertisement
Articles by William Chaplin
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Assessing the opportunities, considerations and implications of decentralized trials—and why they’re here to stay
Advertisement
Latest Updated Articles
Lightship’s Approach to Accessible, Representative, and Impactful Clinical TrialsPublished: February 13th 2025 | Updated: March 4th 2025
Accelerate Inclusive Enrollment and Delivery with LightshipPublished: February 19th 2025 | Updated: February 26th 2025
- Examining the Impact of Exclusionary Behaviors on Team Dynamics
Published: March 24th 2023 | Updated:
Trials and Tribulations of Electronic Patient Consent: Removing Barriers to eConsent AdoptionPublished: April 28th 2021 | Updated:
Sticking to the Plan: Undue Burden Created by Protocol DeviationsPublished: July 26th 2024 | Updated:
Phase III PERSEUS Trial Data Show Darzalex Faspro Combo Improves Survival in Newly Diagnosed Multiple MyelomaPublished: January 31st 2024 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Driving Data Innovation and AI Adoption in Clinical Trials: A Q&A with Novo Nordisk’s VP of Data Systems Innovation
2
Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer
3
Spinogenix Receives Positive FDA Feedback for SPG601 in Fragile X Syndrome
4
How AI Can Help Physicians Identify Eligible Trials Faster
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
